Retinitis Pigmentosa Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2019 - 2030

Retinitis Pigmentosais a group of eye disorders which causes progressive degeneration of retina.  In this case, peripheral vision gradually decreases and eventually lost in most cases and central vision is usually preserved until late in these conditions. Some forms of RP can be associated with deafness, obesity, kidney disease and other health issues.Retina Pigmentosa starts in childhood. Most of the people will lose much of their sight by early adulthood.

There are different types of RP such as Autosomal Recessive Retinitis Pigmentosa, Autosomal Dominant Retinitis Pigmentosa and X-Linked Retinitis Pigmentosa. RP is diagnosed by Ophthalmoscope, Visual Field Test, Electroretinigram, and Genetic Test. Generally RP is treated with Acetazolamide, vitamin A palmitate, if the condition get worse then retinal implant is recommended.

Key Developments:

• In March 2017, Nightstar in collaboration with Professor Robert MacLaren (Oxford team) and Professor Paulo Stanga started a  Phase I/II clinical trial of gene therapy for X-linked Retinitis Pigmentosa to investigate the safety, tolerability and efficacy of a retinal gene therapy with an adeno-associated viral (AAV) vector encoding the defective gene Retinitis Pigmentosa GTPaseRegulater (RPGR)
• In November 2015, RetroSense commenced Phase I/IIa, Open-Label, Dose-Escalation Study of Safety and Tolerability of Intravitreal RST-001 a potential optogenetictherapyin Patients with Advanced Retinitis Pigmentosa (RP), In August 2016 RetroSense Therapeutics received patent protection for the methods of restoring or improving vision using optogenetic approaches in USA. In September 2016, Allergan acquired RST 001 from RetroSense Therapeutics